Results 21 to 30 of about 39,758 (253)

Failure of platelet function analyser 200 to demonstrate clinical clopidogrel resistance in a patient undergoing intracranial vascular stenting. [PDF]

BMJ Case Rep, 2020
Bell H, Steinfort B, Pasalic L, Dexter M.   +3 more
europepmc   +3 more sources

Comparison of Light Transmission Aggregometry and VerifyNow in Detecting Clopidogrel Resistance and Factors Affecting Clopidogrel Resistance in AMI-EST Patients Undergoing Percutaneous Coronary Intervention: A Cross-Sectional Study

Indonesian Biomedical Journal, 2021
BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in ...
Astuti Giantini, Ina Susianti Timan, Erlin Listiyaningsih, Rahajuningsih Dharma, Rianto Setiabudy, Idrus Alwi, Lia Gardenia Partakusuma, Nuri Dyah Indrasari, Alida Roswita Harahap, Siskawati Suparmin, Windy Sahar, Renan Sukmawan   +11 more
doaj   +1 more source

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. [PDF]

PLoS ONE, 2014
Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to ...
Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid   +6 more
doaj   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI

Clinical and Applied Thrombosis/Hemostasis, 2022
Since aspirin and clopidogrel are the widely and conventionally used drugs to treat acute myocardial infarction after percutaneous coronary intervention (PCI), it is important to explore potential risk factors of their resistance.
Lijie Zhang PhD, MD, Ying Lv PhD, MD, Jianyu Dong PhD, MD, Nana Wang MSc, Zhan Zhan MSc, Yuan Zhao BSc, Shanshan Jiang PhD, MD   +6 more
doaj   +1 more source

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

Frontiers in Cardiovascular Medicine, 2023
BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo, Yao Lu, Fei Guo, Aihua Wu, Yuesong Weng   +4 more
doaj   +1 more source

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

BMC Cardiovascular Disorders, 2022
Backgrounds Remarkable interindividual variability in clopidogrel response is observed, genetic polymorphisms in P2RY12 and its signal pathway is supposed to affect clopidogrel response in CHD patients.
Yan-Jiao Zhang, Dong-Jie Li, Zhong-Yi Li, Xiao-Lei Hu, He Li, Qi-Lin Ma, Xiao-Ping Chen   +6 more
doaj   +1 more source

Clopidogrel Resistance

American Journal of Therapeutics, 2010
Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular treatment. This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality.
Jaya Prakash, Sugunaraj, Chandrasekar, Palaniswamy, Dhana Rekha, Selvaraj, Sri Krishna, Chaitanya Arudra, Rishi, Sukhija   +4 more
openaire   +4 more sources

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. [PDF]

, 2014
ObjectiveThere is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among ...
Chang, Ku-Chou, Lee, Hsuei-Chen, Lee, Jiann-Der, Lee, Meng, Lee, Tsong-Hai, Ovbiagele, Bruce, Rao, Neal M, Saver, Jeffrey L, Wang, Hui-Hsuan, Wu, Chih-Ying, Wu, Yi-Ling   +10 more
core   +1 more source

The stent thrombosis in Belgium (STIB) scoring system reliability in Indonesia patients and the modified STIB scoring (M-STIB)

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023
Introduction Clopidogrel is recommended as an alternative to Acetyl Salicylic Acid (ASA), the first-line drug for secondary stroke prevention. Clopidogrel resistance in Indonesia is reportedly 15.8%.
Rakhmad Hidayat, Al Rasyid, Salim Harris, Alida R. Harahap, Herqutanto, Melva Louisa, Erlin Listiyaningsih, Aldy Safruddin Rambe, Tonny Loho   +8 more
doaj   +1 more source